Filings & corporate actions
79 results filed
CSVNext results · Q2 FY27
Expected 29 Oct 2026 – 4 Nov 2026
Estimate: filed 29–35 days after quarter end, last 5 times
Dividend
₹32.00 per share · last 5 Aug 2026
2026
- 5 AugdividendDividend · ₹32.00 per share-2.5%
- 30 JulresultsResults · Q1 FY27 · consolidated and standalone+0.8%NSE
- 14 JulshareholdingShareholding · 30 Jun 2026-0.4%NSE
- 5 MayresultsResults · Q4 FY26 · consolidated and standalone+6.9%NSE
- 13 AprshareholdingShareholding · 31 Mar 2026+3.3%NSE
- 30 JanresultsResults · Q3 FY26 · consolidated and standalone+0.9%NSE
- 12 JanshareholdingShareholding · 31 Dec 2025-1.3%NSE
Reaction to results · all yearsrose on day 0 in 51 of 78 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 30 Jul 2026 | +0.8% | +1.5% | +3.5% | 1.9× |
| Q4 FY26 | 5 May 2026 | +6.9% | +7.8% | +1.7% | 9.3× |
| Q3 FY26 | 30 Jan 2026 | +0.9% | +2.5% | +7.6% | 0.3× |
| Q2 FY26 | 3 Nov 2025 | +2.8% | +1.1% | +2.7% | 2.8× |
| Q1 FY26 | 28 Jul 2025 | +2.0% | -4.7% | -9.4% | 0.7× |
| Q4 FY25 | 30 Apr 2025 | -4.5% | -6.2% | -7.2% | 1.7× |
| Q3 FY25 | 30 Jan 2025 | +0.7% | +0.8% | -7.1% | 2.5× |
| Q2 FY25 | 29 Oct 2024 | +0.1% | +6.5% | +0.3% | 0.8× |
| Q1 FY25 | 30 Jul 2024 | +6.5% | +16.2% | +24.5% | 4.8× |
| Q4 FY24 | 2 May 2024 | +6.7% | +6.4% | +4.4% | 29.2× |
| Q3 FY24 | 31 Jan 2024 | +0.3% | +1.3% | +1.6% | 4.8× |
| Q2 FY24 | 31 Oct 2023 | +3.6% | +2.2% | +12.1% | 3.7× |
| Q1 FY24 | 27 Jul 2023 | +4.1% | +12.5% | +11.1% | 17.4× |
| Q4 FY23 | 5 May 2023 | -1.5% | -2.1% | +6.2% | 2.9× |
| Q3 FY23 | 2 Feb 2023 | +0.3% | +1.6% | -1.4% | 1.4× |
| Q2 FY23 | 4 Nov 2022 | -0.8% | +1.9% | -1.7% | 0.9× |
| Q1 FY23 | 29 Jul 2022 | +0.5% | +0.6% | +7.7% | 2.4× |
| Q4 FY22 | 11 May 2022 | +3.1% | +2.9% | +6.9% | 1.1× |
| Q3 FY22 | 31 Jan 2022 | -1.1% | -3.9% | -20.8% | 0.7× |
| Q2 FY22 | 1 Nov 2021 | +4.2% | +1.6% | -1.9% | 1.7× |
| Q1 FY22 | 30 Jul 2021 | -4.3% | -4.1% | -6.8% | 2.1× |
| Q4 FY21 | 1 May 2021 | -0.2% | +9.2% | +5.1% | 1.5× |
| Q3 FY21 | 3 Feb 2021 | +3.1% | +2.5% | 0.0% | 7.3× |
| Q2 FY21 | 4 Nov 2020 | +0.3% | -3.6% | -0.9% | 4.7× |
| Q1 FY21 | 31 Jul 2020 | +7.7% | +12.0% | +3.8% | 6.1× |
| Q4 FY20 | 21 May 2020 | +3.4% | +5.9% | +0.9% | 5.8× |
| Q3 FY20 | 6 Feb 2020 | +8.9% | +21.5% | +21.4% | 6.6× |
| Q2 FY20 | 6 Nov 2019 | +1.0% | -2.7% | -2.5% | 3.3× |
| Q1 FY20 | 1 Aug 2019 | +8.4% | +8.2% | +15.6% | 8.1× |
| Q4 FY19 | 8 May 2019 | +0.6% | -2.0% | -5.3% | 0.4× |
| Q3 FY19 | 1 Mar 2019 | +0.8% | +0.7% | +5.5% | 0.7× |
| Q2 FY19 | 21 Nov 2018 | -3.5% | +1.8% | -1.4% | 0.7× |
| Q1 FY19 | 7 Aug 2018 | +4.3% | +4.4% | +11.8% | 1.1× |
| Q4 FY18 | 26 May 2018 | +5.1% | -6.8% | +4.2% | 1.3× |
| Q3 FY18 | 16 Mar 2018 | +2.2% | -1.2% | -0.3% | 1.4× |
| Q2 FY18 | 1 Nov 2017 | -0.9% | -2.6% | +13.9% | 1.1× |
| Q1 FY18 | 21 Aug 2017 | -4.3% | -0.8% | -0.7% | 1.9× |
| Q4 FY17 | 15 May 2017 | 0.0% | +2.6% | -5.4% | 0.4× |
| Q3 FY17 | 25 Jan 2017 | +1.2% | +0.9% | +1.6% | 1.2× |
| Q2 FY17 | 4 Nov 2016 | +2.1% | -9.3% | 0.0% | 2.1× |
| Q1 FY17 | 29 Sept 2016 | +0.1% | -2.0% | -0.3% | 0.5× |
| Q4 FY16 | 29 Apr 2016 | -0.6% | +2.0% | +1.6% | 0.8× |
| Q3 FY16 | 3 Feb 2016 | +0.1% | +0.9% | +5.3% | 1.5× |
| Q1 FY16 | 19 Nov 2015 | -0.5% | -1.4% | -4.6% | 0.7× |
| Q2 FY16 | 2 Nov 2015 | +0.7% | -7.1% | -11.1% | 0.5× |
| Q4 FY15 | 19 May 2015 | +1.7% | +10.2% | +6.6% | 0.9× |
| Q3 FY15 | 5 Feb 2015 | -1.0% | +2.3% | +21.7% | 0.3× |
| Q2 FY15 | 3 Nov 2014 | -1.6% | +13.0% | +34.2% | 0.9× |
| Q1 FY15 | 11 Aug 2014 | -1.7% | +5.5% | +12.0% | 0.3× |
| Q4 FY14 | 8 May 2014 | -4.5% | -3.7% | +9.7% | 0.8× |
| Q3 FY14 | 29 Jan 2014 | -1.3% | +0.6% | +10.4% | 0.7× |
| Q2 FY14 | 6 Nov 2013 | +1.0% | +5.3% | +2.2% | 0.6× |
| Q1 FY14 | 2 Aug 2013 | -3.0% | -3.6% | -3.7% | 0.3× |
| Q4 FY13 | 21 May 2013 | +5.3% | +1.5% | -1.9% | 1.6× |
| Q3 FY13 | 23 Jan 2013 | +20.0% | +54.7% | +46.6% | 36.5× |
| Q2 FY13 | 30 Oct 2012 | -3.7% | -6.3% | -8.7% | 1.2× |
| Q1 FY13 | 19 Jul 2012 | +2.1% | +0.6% | +9.1% | 4.5× |
| Q4 FY12 | 3 May 2012 | +1.2% | +2.0% | +13.3% | 0.5× |
| Q3 FY12 | 24 Jan 2012 | +6.8% | +7.5% | +28.0% | 7.7× |
| Q2 FY12 | 24 Oct 2011 | -0.5% | +2.9% | -0.5% | 1.5× |
| Q1 FY12 | 29 Jul 2011 | -0.8% | -12.5% | -13.6% | 0.7× |
| Q4 FY11 | 30 Apr 2011 | +3.1% | -0.4% | +9.6% | 3.0× |
| Q3 FY11 | 20 Jan 2011 | +19.2% | +12.8% | +7.3% | 65.3× |
| Q2 FY11 | 22 Oct 2010 | +0.9% | -5.1% | -11.0% | 3.2× |
| Q1 FY11 | 30 Jul 2010 | +2.4% | -1.3% | +16.6% | 1.0× |
| Q4 FY10 | 6 May 2010 | +0.3% | -4.6% | -2.0% | 1.0× |
| Q3 FY10 | 29 Jan 2010 | -0.4% | -0.4% | +4.1% | 0.3× |
| Q2 FY10 | 29 Oct 2009 | -3.5% | -3.5% | 0.0% | 1.6× |
| Q1 FY10 | 30 Jul 2009 | 0.0% | -3.2% | +3.8% | 0.6× |
| Q4 FY09 | 15 May 2009 | +17.0% | +42.0% | +33.0% | 0.0× |
| Q3 FY09 | 30 Jan 2009 | 0.0% | +4.3% | -3.3% | 0.3× |
| Q2 FY09 | 23 Oct 2008 | +2.0% | +1.0% | -8.1% | 1.8× |
| Q1 FY09 | 30 Jul 2008 | +3.5% | +3.5% | 0.0% | 2.1× |
| Q4 FY08 | 30 Apr 2008 | +5.5% | +9.2% | +1.2% | 3.1× |
| Q3 FY08 | 30 Jan 2008 | +5.6% | +7.7% | +5.6% | 0.8× |
| Q2 FY08 | 30 Oct 2007 | -0.6% | -4.3% | -0.6% | 0.5× |
| Q1 FY08 | 30 Jul 2007 | -4.7% | -8.9% | -11.1% | 0.4× |
| Q4 FY07 | 27 Apr 2007 | +6.8% | +9.1% | +11.4% | 8.4× |
| Average | +1.9% | +2.8% | +4.0% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSVRevenue YoY+24.8%
Profit YoY+30.9%
Interest cost YoY—
Revenue QoQ+14.4%
Profit QoQ+25.3%
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Profit | — | — | — | — | — | — |
Key data
CSVOpen3,492.10
Day range3,486.00 – 3,585.00
52-week range2,329.90 – 3,796.00
From 52w high-5.9%
RSI (14)52.9
ATR (14)96.41
Volume1.09L
Avg volume (20D)97.9K
Rel volume1.12×
Volatility (1Y)25.4%
Turnover₹39.1Cr
SMA 50 / 2003,538.23 / 3,110.60
Delivery percentage
Latest · 6 Oct 202653.0%
20-day avg52.5%
1-year avg54.2%
Percentile (own history)58th
Range6.5–95.3%
Sessions1,731
Over the last 20 sessions AJANTPHARM settled 52.5% of its traded quantity, which is above average for an NSE equity. That is in line with its own one-year average of 54.2%. The latest session ranks higher than 58% of the 1,731 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | +2.51% | +1.37% | +1.49% | +7.81% | +28.02% | +44.95% |
Valuation
CSVMarket cap₹44,653 Cr
P/E (TTM)39.3
EPS (TTM)90.82
Shares outstanding12.54Cr
Listed29 May 2000
Ownership
CSVPromoter—
Promoter Δ QoQ—
Public—
FII—
DII—
Pledged—
Quarterly results · consolidated
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 1,353.7 | 1,374.8 | 1,421.6 | 1,626.0 |
| YoY chg | — | — | +21.5% | +24.8% |
| Net profit (₹ Cr) | 260.2 | 273.8 | 266.7 | 334.2 |
| YoY chg | — | — | +18.4% | +30.9% |
| Net margin | 19.2% | 19.9% | 18.8% | 20.6% |
| EPS | 20.82 | 21.91 | 21.34 | 26.72 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 63.48% · public 36.52%2021-092026-06
- Promoter
- Public and others
- Promoter
- 63.48%
- Public
- 36.52%
- Promoter change
- -2.77 pp
- Filed
- 14 Jul 2026
- FII
- 7.68%
- DII
- 21.80%
- Promoter pledged
- 22.53%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSV₹ crore, as filed
| Q2 FY24 | Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26A | Q1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 1,028.4 | 1,105.2 | 1,054.1 | 1,144.9 | 1,186.6 | 1,146.1 | 1,170.4 | 1,302.7 | 1,353.7 | 1,374.8 | 1,421.6 | 1,626.0 | |
| Other income | 21.3 | 13.6 | 35.5 | 26.5 | 19.5 | 30.4 | 18.1 | 26.3 | 59.3 | 25.0 | 61.4 | 70.9 | |
| Total income | 1,049.8 | 1,118.7 | 1,089.6 | 1,171.4 | 1,206.1 | 1,176.6 | 1,188.5 | 1,329.0 | 1,413.1 | 1,399.8 | 1,483.1 | 1,696.9 | |
| Total expenses | 773.8 | 827.8 | 811.5 | 849.3 | 915.9 | 869.2 | 919.1 | 997.9 | 1,072.3 | 1,041.2 | 1,136.0 | 1,250.1 | |
| └ Finance costs | 2.3 | 2.5 | 1.5 | 0.7 | 6.0 | 7.9 | 6.1 | 5.3 | 3.4 | 5.1 | 2.4 | 3.2 | |
| └ Depreciation | 33.7 | 34.3 | 34.3 | 34.0 | 34.4 | 36.0 | 39.8 | 41.3 | 43.0 | 43.5 | 45.4 | 44.5 | |
| Profit before tax | 275.9 | 290.9 | 278.0 | 322.1 | 290.2 | 307.4 | 269.4 | 331.1 | 340.8 | 358.6 | 347.1 | 446.8 | |
| Tax expense | 80.6 | 80.9 | 75.3 | 76.4 | 73.8 | 74.5 | 44.2 | 75.8 | 80.6 | 84.8 | 80.4 | 112.6 | |
| Net profit | 195.3 | 210.0 | 202.7 | 245.8 | 216.5 | 232.9 | 225.3 | 255.3 | 260.2 | 273.8 | 266.7 | 334.2 | |
| EPS | 15.51 | 16.68 | 16.10 | 19.54 | 17.27 | 18.60 | 18.00 | 20.44 | 20.83 | 21.91 | 21.35 | 26.75 | |
| Net margin | 18.99% | 19.00% | 19.23% | 21.47% | 18.24% | 20.32% | 19.25% | 19.60% | 19.22% | 19.91% | 18.76% | 20.56% | |
| PBT margin | 26.83% | 26.32% | 26.38% | 28.13% | 24.46% | 26.82% | 23.02% | 25.42% | 25.18% | 26.08% | 24.42% | 27.48% | |
| Tax rate | 29.22% | 27.80% | 27.09% | 23.70% | 25.41% | 24.24% | 16.39% | 22.89% | 23.66% | 23.66% | 23.17% | 25.20% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 30 Jul 2026.
AJANTPHARM at a glance
- AJANTPHARM closed at ₹3,573.4 on 6 Oct 2026, +2.51% on the day, +45.0% over one year, 5.9% below its 52-week high of ₹3,796.
- Delivery was 53.0% of traded quantity on 6 Oct 2026, the 58th percentile of its own 1,731 sessions with a reading (20-session average 52.5%, 1-year average 54.2%).
- Market capitalisation is ₹44,653 crore at a trailing P/E of 39.3 (trailing EPS ₹90.82).
- Q1 FY27 results (consolidated, filed 30 Jul 2026): revenue ₹1,626 crore (+24.8% year on year), net profit ₹334 crore (+30.9%); the price moved +0.8% on the first session after.
- Promoters held 63.48% at 30 Jun 2026, down 2.77 percentage points on the previous filing, with 22.53% of promoter shares pledged.
- Q2 FY27 results are expected between 29 Oct 2026 and 4 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE031B01049
SeriesEQ
Listed29 May 2000
History from5 Jun 2000
Sessions6,546
Turnover rank#581
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE